1,7-Bis(4′-hydroxy-3′-trifluoromethoxyphenyl)4-methoxycarbonylethyl-1,6-heptadiene-3,5-dione) (FMeC1), a novel curcumin derivative, significantly decreased the insoluble Aβ deposits, glial activation, and ameliorated the cognitive deficits in APP/PS1 double transgenic AD mice [45]. The gene discussed is APP; the disease is Alzheimer disease.